vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $13.8M, roughly 1.2× CB Financial Services, Inc.). On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 19.9%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CBFV vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $16.1M |
| Net Profit | — | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | -2.8% |
| Net Margin | — | -7.8% |
| Revenue YoY | 19.9% | 27.3% |
| Net Profit YoY | — | -182.0% |
| EPS (diluted) | $0.90 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $16.1M | ||
| Q3 25 | $2.4M | $17.0M | ||
| Q2 25 | $13.5M | $15.0M | ||
| Q1 25 | $12.1M | $13.1M | ||
| Q4 24 | $13.2M | $12.6M | ||
| Q3 24 | $12.7M | $14.6M | ||
| Q2 24 | $12.2M | $14.9M | ||
| Q1 24 | $13.5M | $13.0M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $-5.7M | $-2.3M | ||
| Q2 25 | $3.9M | $-3.8M | ||
| Q1 25 | $1.9M | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $3.2M | $-2.4M | ||
| Q2 24 | $2.6M | $-3.4M | ||
| Q1 24 | $4.2M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | 38.1% | -2.8% | ||
| Q3 25 | -289.8% | -9.0% | ||
| Q2 25 | 35.0% | -19.2% | ||
| Q1 25 | 19.3% | -25.3% | ||
| Q4 24 | 23.1% | 17.7% | ||
| Q3 24 | 31.2% | -19.8% | ||
| Q2 24 | 26.4% | -19.7% | ||
| Q1 24 | 37.9% | -77.4% |
| Q4 25 | — | -7.8% | ||
| Q3 25 | -235.2% | -13.6% | ||
| Q2 25 | 29.3% | -25.3% | ||
| Q1 25 | 15.8% | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | 25.3% | -16.3% | ||
| Q2 24 | 21.8% | -22.6% | ||
| Q1 24 | 31.1% | -80.1% |
| Q4 25 | $0.90 | $-0.04 | ||
| Q3 25 | $-1.07 | $-0.09 | ||
| Q2 25 | $0.74 | $-0.16 | ||
| Q1 25 | $0.35 | $-0.18 | ||
| Q4 24 | $0.45 | $0.10 | ||
| Q3 24 | $0.60 | $-0.12 | ||
| Q2 24 | $0.51 | $-0.17 | ||
| Q1 24 | $0.82 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $157.5M | $31.9M |
| Total Assets | $1.5B | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $24.1M | ||
| Q3 25 | $55.9M | $24.9M | ||
| Q2 25 | $64.5M | $20.3M | ||
| Q1 25 | $61.3M | $21.1M | ||
| Q4 24 | $49.6M | $20.3M | ||
| Q3 24 | $147.3M | $22.5M | ||
| Q2 24 | $142.6M | $23.9M | ||
| Q1 24 | $73.7M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $157.5M | $31.9M | ||
| Q3 25 | $152.5M | $25.9M | ||
| Q2 25 | $148.4M | $19.2M | ||
| Q1 25 | $148.3M | $21.5M | ||
| Q4 24 | $147.4M | $20.1M | ||
| Q3 24 | $149.1M | $10.9M | ||
| Q2 24 | $142.9M | $11.3M | ||
| Q1 24 | $141.6M | $13.0M |
| Q4 25 | $1.5B | $94.6M | ||
| Q3 25 | $1.5B | $85.2M | ||
| Q2 25 | $1.5B | $81.2M | ||
| Q1 25 | $1.5B | $85.0M | ||
| Q4 24 | $1.5B | $80.2M | ||
| Q3 24 | $1.6B | $64.0M | ||
| Q2 24 | $1.6B | $65.2M | ||
| Q1 24 | $1.5B | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-6.3M |
| Free Cash FlowOCF − Capex | $17.2M | — |
| FCF MarginFCF / Revenue | 124.1% | — |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-6.3M | ||
| Q3 25 | $4.6M | $-2.4M | ||
| Q2 25 | $4.1M | $-942.0K | ||
| Q1 25 | $4.0M | $-2.8M | ||
| Q4 24 | $6.8M | $2.2M | ||
| Q3 24 | $3.1M | $-1.2M | ||
| Q2 24 | $-1.2M | $-5.2M | ||
| Q1 24 | $3.3M | $-5.0M |
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $-2.4M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.5% | — | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | -19.6% | — | ||
| Q1 24 | 17.0% | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 25.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 10.0% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
